# Investigating the molecular mechanisms of the “Astragalus-Codonopsis” herb pair in treating diabetes: a network pharmacology and bioinformatics approach with molecular docking validation

**Authors:** Jinliang Yang, Mingyang Li, Ziyue Zhu, Fengling Han, Yanyan Ma, Jinbo Hou, Qingfeng Zhao, Hui Yuan, XiuMei Li

PMC · DOI: 10.3389/fbioe.2025.1618575 · 2025-07-07

## TL;DR

This study explores how the Astragalus-Codonopsis herb pair helps treat diabetes by identifying key compounds and their molecular mechanisms.

## Contribution

The study identifies rhamnolitrin and folic acid as key components and reveals their synergistic effects on GSK3β in treating diabetes.

## Key findings

- Rhamnolitrin and folic acid were confirmed as key active components regulating the IRSP pathway in diabetes treatment.
- Molecular docking and simulations showed stable binding of these compounds with the GSK3β protein.
- Alanine scanning and DFT calculations validated key interactions and binding mechanisms with GSK3β.

## Abstract

Astragalus membranaceus and Codonopsis pilosula are widely used in traditional chinese medicine for the treatment of diabetes because of their notable hypoglycemic pharmacological effects. Studies have indicatedthat the active compounds in the Astragalus-Codonopsis herb pair may exert their hypoglycemic effects through the modulation of the insulin receptor (IRSP) signaling pathway. In this study, the rhamnolitrin and folic acid were confirmed as the key active components in the Astragalus-Codonopsis herb pair that regulate the IRSP, with their synergistic mechanisms in Type 2 Diabetes Mellitus (T2DM) being further systematically explored by network pharmacology combined with DFT theoretical calculation, molecular docking, molecular dynamics simulation and alanine scanning mutation technology. The results suggest that GSK3β is a critical target through which rhamnolitrin and folic acid exert their anti-diabetic effects. Subsequent molecular docking and molecular dynamics simulations confirmed that both active compounds selected in this study can bind stably with the GSK3β protein. Further alanine scanning mutagenesis experiments validated the importance of key amino acid residues in ligand-receptor interactions. Finally, DFT theoretical calculations provided a detailed elucidation of the binding mechanism between the core components (rhamnolitrin and folic acid) and the target protein GSK3β. This study not only revealed the molecular mechanism of Astragalus-Codonopsis for the treatment of type 2 diabetes, provided a theoretical basis for its clinical application, but also provided a potential molecular target for the development of new anti-diabetes drugs.

## Linked entities

- **Proteins:** GSK3B (glycogen synthase kinase 3 beta)
- **Chemicals:** folic acid (PubChem CID 135398658)
- **Diseases:** Type 2 Diabetes Mellitus (MONDO:0005148), diabetes (MONDO:0005015)
- **Species:** Astragalus membranaceus (taxon 649199), Codonopsis pilosula (taxon 86864)

## Full-text entities

- **Genes:** INSR (insulin receptor) [NCBI Gene 3643] {aka CD220, HHF5}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932]
- **Diseases:** diabetes (MESH:D003920), T2DM (MESH:D003924)
- **Chemicals:** folic acid (MESH:D005492), rhamnolitrin (-)
- **Species:** Codonopsis pilosula (species) [taxon 86864], Astragalus membranaceus (species) [taxon 649199]

## Figures

13 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12277270/full.md

---
Source: https://tomesphere.com/paper/PMC12277270